Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5
Novartis (United States) · Novartis (Switzerland) · +2 more institutions
Abstract
5-Methylthioadenosine phosphorylase (MTAP) is a key enzyme in the methionine salvage pathway. The MTAP gene is frequently deleted in human cancers because of its chromosomal proximity to the tumor suppressor gene CDKN2A. By interrogating data from a large-scale short hairpin RNA-mediated screen across 390 cancer cell line models, we found that the viability of MTAP-deficient cancer cells is impaired by depletion of the protein arginine methyltransferase PRMT5. MTAP-deleted cells accumulate the metabolite methylthioadenosine (MTA), which we found to inhibit PRMT5 methyltransferase activity. Deletion of MTAP in MTAP-proficient cells rendered them sensitive to PRMT5 depletion. Conversely, reconstitution of MTAP…
Citation impact
- FWCI
- 26.81
- Percentile
- 100%
- References
- 29
Authors
44- KJKonstantinos J. MavrakisCorresponding
Novartis (United States)
- ERE. Robert McDonaldCorresponding
Novartis (United States)
- MRMichael R. SchlabachCorresponding
Novartis (United States)
- ÉBÉric BillyCorresponding
Novartis (Switzerland), Novartis Institutes for BioMedical Research
- GRGregory R. HoffmanCorresponding
Novartis (United States)
Topics & keywords
- Methionine
- CDKN2A
- Protein arginine methyltransferase 5
- Cancer research
- Metabolism
- Cancer cell
- Gene
- Cancer